Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Company Deals

AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products

Fineline Cube Apr 17, 2026
Company Deals

Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform

Fineline Cube Apr 17, 2026
Company Deals

Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu

Fineline Cube Apr 17, 2026
Company Deals Digital

Tigermed and Alibaba Cloud Forge Alliance to Build AI-Powered Ecosystem for Intelligent Clinical Trials

Fineline Cube Apr 17, 2026
Policy / Regulatory

China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives

Fineline Cube Apr 15, 2026
Company Drug

Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026

Fineline Cube Apr 20, 2026
Company Drug

Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026

Fineline Cube Apr 20, 2026
Policy / Regulatory

NHSA Seeks Expert Opinions on VBP Drug Quality and Efficacy

Fineline Cube Jan 20, 2025

The National Healthcare Security Administration (NHSA) has released a letter titled “Letter on Requesting Assistance...

Company Drug

Junshi Biosciences’ Toripalimab Gains TGA Approval for Nasopharyngeal Carcinoma

Fineline Cube Jan 20, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving marketing approval...

Company

Inscinstech Secures C-Series Financing for Biopharma Expansion

Fineline Cube Jan 19, 2025

Inscinstech Co., Ltd., a leading intelligent technology company based in Suzhou, has successfully completed a...

Company

Raytone Bio Completes Angel Round to Advance iSus® Platform

Fineline Cube Jan 18, 2025

Raytone Bio, a Shenzhen-based biopharmaceutical company, has announced the completion of a multi-million RMB Angel...

Company Drug

Aosaikang’s Limertinib Approved for EGFR T790M-Mutated NSCLC

Fineline Cube Jan 18, 2025

Jiangsu Aosaikang Pharmaceutical Co., Ltd (ASK Pharm, SHE: 002755) has recently received approval from the...

Company Drug

Johnson & Johnson Submits NDA for TAR-200 in High-Risk Bladder Cancer

Fineline Cube Jan 17, 2025

US-based Johnson & Johnson (J&J, NYSE: JNJ) has announced the initiation of the submission of...

Company Drug

Eli Lilly’s Omvoh Approved by FDA for Crohn’s Disease Treatment

Fineline Cube Jan 17, 2025

US major Eli Lilly and Company (NYSE: LLY) has announced receiving marketing approval from the...

Company Deals

IVIEW Therapeutics Secures Series A++ Funding for Ophthalmology Pipeline

Fineline Cube Jan 17, 2025

IVIEW Therapeutics Inc., an ophthalmology biotech operating out of the US and China, has reportedly...

Company Drug

Boehringer Ingelheim’s Iclepertin Fails to Meet Phase III Study Endpoints

Fineline Cube Jan 17, 2025

German giant Boehringer Ingelheim has disclosed negative top-line results from the Phase III CONNEX study...

Company Drug

Telix Pharmaceuticals’ TLX591-CDx Approved in Europe via Decentralized Procedure

Fineline Cube Jan 17, 2025

Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that the marketing filing in Europe via...

Policy / Regulatory

NMPA Implements Regulatory Reforms for Drug and Medical Device Industries

Fineline Cube Jan 17, 2025

The National Medical Products Administration (NMPA) has released a notification regarding the implementation of the...

Company Deals Drug

Daiichi Sankyo Acquires Gatipotuzumab IP Rights for $132.5M

Fineline Cube Jan 17, 2025

Japan-based Daiichi Sankyo Company, Ltd (TYO: 4568) has announced an investment of USD 132.5 million...

Policy / Regulatory

NHSA Pushes for Real-Time Settlement Reform in Basic Medical Insurance

Fineline Cube Jan 17, 2025

The National Healthcare Security Administration (NHSA) has released a notification to promote the real-time settlement...

Company Deals

a16z Bio + Health Launches Biotech Ecosystem Venture Fund

Fineline Cube Jan 17, 2025

Andreessen Horowitz (a16z) Bio + Health has announced the establishment of the Biotech Ecosystem Venture...

Company Drug

Impact Therapeutics’ Senaparib Cleared by NMPA for Ovarian Cancer Therapy

Fineline Cube Jan 17, 2025

China-based Impact Therapeutics has announced receiving marketing clearance from the National Medical Products Administration (NMPA)...

Company

Siemens Lays Foundation for New Medical Equipment Base in Shenzhen

Fineline Cube Jan 17, 2025

Siemens (Shenzhen) Magnetic Resonance Co., Ltd., a wholly-owned subsidiary of Siemens Ltd., China, has officially...

Company Deals

Fujian Haixi Pharmaceuticals Files for Hong Kong IPO

Fineline Cube Jan 17, 2025

China-based Fujian Haixi Pharmaceuticals Co., Ltd., a commercial-stage innovative pharmaceutical company, has made an initial...

Company Drug

SciClone and Menarini Submit NDA for Vaborem in China

Fineline Cube Jan 17, 2025

China-based SciClone Pharmaceuticals Inc and its Italy-based strategic partner Menarini have announced the submission of...

Company Deals

Servier and Google Cloud Extend Partnership to Advance AI in Drug Development

Fineline Cube Jan 17, 2025

France-based Servier Group and US technology firm Google Cloud have announced an expansion to their...

Company Deals

Cathay Biotech Plans $901M Private Placement to Boost Bio-Based Materials

Fineline Cube Jan 17, 2025

Shanghai-based Cathay Biotech Inc. (SHA: 688065) has announced plans to raise RMB 6.6 billion (USD...

Posts pagination

1 … 212 213 214 … 653

Recent updates

  • Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026
  • Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026
  • Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio
  • AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products
  • Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026

Company Drug

Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026

Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Company Deals

AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.